nach oben

International Urology and Nephrology

Erschienen in:

11.12.2017 | Nephrology - Original Paper

Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2

verfasst von: Libin Ma, Hua Li, Shuchao Zhang, Xiaoling Xiong, Kean Chen, Peiwu Jiang, Kang Jiang, Gang Deng

Erschienen in: International Urology and Nephrology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Emodin is a natural active component extracted from Chinese herbs. In this study, we investigated the therapeutic effect of emodin on surgery-induced renal fibrosis in rat. Moreover, the function of Smad ubiquitination regulatory factor 2 (Smurf 2) was further studied in vitro.

Methods

The renal fibrosis rat model was established via 5/6 renal mass reduction. The histopathological abnormalities of renal tissues in rats were tested via staining method and microscopic examination. Renal function indicators, the serum creatinine, blood urea nitrogen and total urinary protein were measured via spectrophotometric method. The renal tissues were tested via Western blotting and real-time quantitative PCR. Moreover, Smurf 2 protein expression under different conditions and its regulatory function in vitro was measured via Western blotting.

Results

Our results showed that the histopathological abnormalities, the decrease in rat body weight and the abnormal renal function caused by renal fibrosis were improved by emodin. Further, mRNA expression of TGF-β1 was decreased by emodin. Furthermore, extracellular matrix (ECM) components as well as TGF-β1/Smad signaling-related Smurf 2 were decreased by emodin both in vivo and in vitro. The protein level of mothers against decapentaplegic homolog 7 (Smad7) was up-regulated. In addition, ECM components were increased by Smurf 2 over-expression and these effects were weakened by emodin co-treatment in vitro.

Conclusion

Emodin showed an anti-fibrosis effect in surgery-induced renal fibrotic rats. And this effect was potentially achieved via down-regulating expressions of TGF-β1 and Smurf 2 and up-regulating Smad7 expression.

Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ (2010) Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 128(1):61–81. https://doi.org/10.1016/j.pharmthera.2010.05.006 CrossRefPubMed

Fogo AB (2001) Progression and potential regression of glomerulosclerosis. Kidney Int 59(2):804–819. https://doi.org/10.1046/j.1523-1755.2001.059002804.x CrossRefPubMed

Rodriguez-Pena A, Prieto M, Duwel A, Rivas JV, Eleno N, Perez-Barriocanal F, Arevalo M, Smith JD, Vary CP, Bernabeu C, Lopez-Novoa JM (2001) Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant 16(Suppl 1):34–39CrossRefPubMed

Nogueira A, JoÃO Pires M, Alexandra Oliveira P (2017) Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In Vivo 31(1):1–22. https://doi.org/10.21873/invivo.11019 CrossRefPubMedPubMedCentral

Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346(6282):371–374. https://doi.org/10.1038/346371a0 CrossRefPubMed

Wolf G (1998) Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 13(5):1131–1142CrossRefPubMed

Weng L, Wang W, Su X, Huang Y, Su L, Liu M, Sun Y, Yang B, Zhou H (2015) The effect of cAMP-PKA activation on TGF-beta1-induced profibrotic signaling. Cell Physiol Biochem 36(5):1911–1927. https://doi.org/10.1159/000430160 CrossRefPubMed

Hewitson TD (2009) Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 296(6):F1239–F1244. https://doi.org/10.1152/ajprenal.90521.2008 CrossRefPubMed

Macias MJ, Martin-Malpartida P, Massague J (2015) Structural determinants of Smad function in TGF-beta signaling. Trends Biochem Sci 40(6):296–308. https://doi.org/10.1016/j.tibs.2015.03.012 CrossRefPubMedPubMedCentral

10.

Lei XF, Fu W, Kim-Kaneyama JR, Omoto T, Miyazaki T, Li B, Miyazaki A (2016) Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice. J Hepatol 64(1):110–117. https://doi.org/10.1016/j.jhep.2015.08.026 CrossRefPubMed

11.

Zhou X, Zang X, Ponnusamy M, Masucci MV, Tolbert E, Gong R, Zhao TC, Liu N, Bayliss G, Dworkin LD, Zhuang S (2016) Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad7 and phosphatase and tensin homolog expression. JASN 27(7):2092–2108. https://doi.org/10.1681/asn.2015040457 CrossRefPubMed

12.

Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, Wrana JL (2001) TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol 3(6):587–595. https://doi.org/10.1038/35078562 CrossRefPubMed

13.

Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6(6):1365–1375CrossRefPubMed

14.

Yang YC, Lim MY, Lee HS (2003) Emodin isolated from Cassia obtusifolia (Leguminosae) seed shows larvicidal activity against three mosquito species. J Agric Food Chem 51(26):7629–7631. https://doi.org/10.1021/jf034727t CrossRefPubMed

15.

Wang JB, Zhao HP, Zhao YL, Jin C, Liu DJ, Kong WJ, Fang F, Zhang L, Wang HJ, Xiao XH (2011) Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L. in treating rat liver injury. PLoS ONE 6(9):e24498. https://doi.org/10.1371/journal.pone.0024498 CrossRefPubMedPubMedCentral

16.

Yang T, Kong B, Kuang Y, Cheng L, Gu J, Zhang J, Shu H, Yu S, Yang X, Cheng J, Huang H (2015) Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1). Int J Clin Exp Pathol 8(3):3418–3425PubMedPubMedCentral

17.

Cha TL, Chuang MJ, Tang SH, Wu ST, Sun KH, Chen TT, Sun GH, Chang SY, Yu CP, Ho JY, Liu SY, Huang SM, Yu DS (2015) Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth. Mol Carcinog 54(3):167–177. https://doi.org/10.1002/mc.22084 CrossRefPubMed

18.

Yao WY, Zhou YF, Qian AH, Zhang YP, Qiao MM, Zhai ZK, Yuan YZ, Yang SL (2015) Emodin has a protective effect in cases of severe acute pancreatitis via inhibition of nuclear factorkappaB activation resulting in antioxidation. Mol Med Rep 11(2):1416–1420. https://doi.org/10.3892/mmr.2014.2789 CrossRefPubMed

19.

Kim DY, Kang TB, Shim DW, Sun X, Han JW, Ji YE, Kim TJ, Koppula S, Lee KH (2014) Emodin attenuates A23187-induced mast cell degranulation and tumor necrosis factor-alpha secretion through protein kinase C and IkappaB kinase 2 signaling. Eur J Pharmacol 723:501–506. https://doi.org/10.1016/j.ejphar.2013.09.066 CrossRefPubMed

20.

Bhadauria M, Nirala SK, Shrivastava S, Sharma A, Johri S, Chandan BK, Singh B, Saxena AK, Shukla S (2009) Emodin reverses CCl induced hepatic cytochrome P450 (CYP) enzymatic and ultrastructural changes: the in vivo evidence. Hepatol Res 39(3):290–300. https://doi.org/10.1111/j.1872-034X.2008.00380.x CrossRefPubMed

21.

Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenfuhrer J, Hasan AA, Tammen H, Alter M, Klein T, Ueda S, Yamagishi S, Okuda S, Hocher B (2016) The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int 89(5):1049–1061. https://doi.org/10.1016/j.kint.2016.01.016 CrossRefPubMed

22.

Peng W, Qiu X-Q, Shu Z-H, Liu Q-C, Hu M-B, Han T, Rahman K, Qin L-P, Zheng C-J (2015) Hepatoprotective activity of total iridoid glycosides isolated from Paederia scandens (lour.) Merr. var. tomentosa. J Ethnopharmacol 174:317–321. https://doi.org/10.1016/j.jep.2015.08.032 CrossRefPubMed

23.

Raij L, Azar S, Keane W (1984) Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26(2):137–143CrossRefPubMed

24.

Abe S, Amagasaki Y, Iyori S, Konishi K, Kato E, Sakaguchi H (1989) Significance of tubulointerstitial lesions in biopsy specimens of glomerulonephritic patients. Am J Nephrol 9(1):30–37CrossRefPubMed

25.

Ono H, Ono Y (1997) Nephrosclerosis and hypertension. Med Clin N Am 81(6):1273–1288CrossRefPubMed

26.

Yoshida Y, Fukuda N, Maeshima A, Yamamoto C, Matsumoto T, Ueno T, Nojima Y, Matsumoto K, Soma M (2011) Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats. J Hypertens 29(1):91–101. https://doi.org/10.1097/HJH.0b013e32834000e2 CrossRefPubMed

27.

Zhang L, Zhang J, Xu C, Zhou X, Wang W, Zheng R, Hu W, Wu P (2015) Lefty-1 alleviates TGF-beta1-induced fibroblast-myofibroblast transdifferentiation in NRK-49F cells. Drug Des Dev Ther 9:4669–4678. https://doi.org/10.2147/dddt.s86770 CrossRef

28.

Meng XM, Chung AC, Lan HY (2013) Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci (London, England: 1979) 124(4):243–254. https://doi.org/10.1042/cs20120252 CrossRef

29.

Lan HY (2003) Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 12(1):25–29. https://doi.org/10.1097/01.mnh.0000049812.98789.97 CrossRefPubMed

30.

Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, Wen P, Yang J (2012) The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol 302(3):F369–F379. https://doi.org/10.1152/ajprenal.00268.2011 CrossRefPubMed

31.

Wrana JL (2000) Regulation of Smad activity. Cell 100(2):189–192CrossRefPubMed

32.

Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389(6651):631–635. https://doi.org/10.1038/39369 CrossRefPubMed

33.

Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, Kitagawa M, Hishida A (2004) Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 101(23):8687–8692. https://doi.org/10.1073/pnas.0400035101 CrossRefPubMedPubMedCentral

34.

Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R (2001) Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 98(3):974–979. https://doi.org/10.1073/pnas.98.3.974 CrossRefPubMedPubMedCentral

35.

Lin X, Liang M, Feng XH (2000) Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 275(47):36818–36822. https://doi.org/10.1074/jbc.C000580200 CrossRefPubMed

Titel: Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2
verfasst von: Libin Ma
Hua Li
Shuchao Zhang
Xiaoling Xiong
Kean Chen
Peiwu Jiang
Kang Jiang
Gang Deng
Publikationsdatum: 11.12.2017
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 2/2018
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-017-1757-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

The effectiveness of multidisciplinary care models for patients with chronic kidney disease: a systematic review and meta-analysis

Kidney transplantation in Romania: two transplant centers experience

What is the place of POEMS syndrome in the current classification of monoclonal gammopathies of renal significance?

Effects of small molecules water that may retard kidney stone formation

Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy